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Abstract
Background: The role of mass drug administration (MDA) and the implementation of transmission reduction measures
are essential to successfully control and eliminate a wide range of NTDs, including the ocular disease trachoma. Immunity
to trachoma infection acts by reducing the duration of an individual’s infectious period and by reducing their infectivity
with each successive infection.
Methods: In this study, we use a model of trachoma infection, which includes population immunity, to explore the
impact of treatment and transmission reduction measures on trachoma prevalence. Specifically, we investigate the
possibility of increasing transmissibility of trachoma arising as MDA and transmission reduction measures are scaled up in
endemic settings.
Results: We demonstrate this increase in transmissibility by calculating the effective reproduction number during several
simulated control programmes and show that it is related to a decrease in the level of immunity in the population.
Conclusions: This effect should be studied in the field by measuring the rate of return of infection and disease in at least
two separate age groups. If the decline of population immunity is operating, it should be accounted for when planning
for the GET2020 goal of eliminating blinding trachoma by 2020.
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Background
Infection with ocular Chlamydia trachomatis (trachoma)
remains the world’s leading infectious cause of blindness. It
is endemic in 53 countries, with an estimated 84 million
visually impaired and in need of treatment, while 1.2 mil-
lion individuals are irreversibly blind [1]. The World Health
Organization (WHO) recommends the use of the SAFE
strategy to help with trachoma control (Surgery, Antibi-
otics, Facial cleanliness, and Environmental changes). Fur-
thermore, it is estimated that 110 million people inhabit
areas in which trachoma is believed to be endemic, and
where the SAFE strategy needs to be implemented [2]. The
WHO advocates eliminating blinding trachoma by 2020,
and the Global Alliance for the Elimination of Trachoma
by 2020 was established to help achieve this goal. The first
GET2020 goal aims to reduce trachomatous inflammation
follicular (TF) prevalence to <5 % in all 1–9 year olds by
2020. Reduced prevalence of active disease will only be
maintained if transmission is reduced sufficiently, and this
relies on the successful implementation of antibiotic treat-
ment as well as long term reductions in overall
transmission.
The role of mass drug administration (MDA) and the
implementation of transmission reduction measures are
essential to successfully control and eliminate a wide
range of infectious diseases, such as: malaria [3], trachoma
[4], schistosomiasis [5–7], onchocerciasis [8], and lymph-
atic filariasis [9]. However, for diseases in which immunity
to infection is acquired through repeated infections, it has
been suggested that dramatically lowering transmission in
a short time period may lead to unintended outcomes on
the prevalence of infection and disease [3, 10–13]; if
transmission is reduced, individuals who have not recently
experienced an infection may have less immune protec-
tion than before transmission was reduced [6, 7, 12].
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Immunity to trachoma acts on at least two levels: first, by
reducing an individual’s bacterial load and therefore infect-
ivity [14–16], and second, by reducing the duration of an
individual’s infectious period with successive infections
[17, 18]. As such, if the rate at which new infections are ac-
quired is reduced, the rate at which immunity to infection
develops will also be reduced. As an individual’s infectivity
and duration of infectiousness are key components of the
basic reproduction number (R0), alterations at the popula-
tion level of these parameters may impact the value of the
effective reproduction number over time.
The possible adverse impact of MDA on R0 and short
term immunity to trachoma was explored in an analysis by
Liu et al. [19]. In this study a stochastic mathematical
model was fitted to prevalence data from an MDA trial
conducted across 32 communities in Tanzania [20, 21]. No
significant change in the value of R0 across the 3 year trial
period was identified, suggesting little to no loss of popula-
tion immunity during this time [19]. However, if loss of
population immunity were playing a role, a clear signal of
increasing R0 may only become apparent after several
years of treatment, and the initial increase may be small.
Data from a single community does not therefore provide
sufficient evidence to suggest that this outcome is not a
possibility in other communities.
The effect of reduced population immunity as a conse-
quence of intensive treatment has also been hypothesised
for genital C. trachomatis infection. Brunham et al. [22, 23]
observed that following the introduction of an intensive
treatment programme in Greater Vancouver, British
Colombia, paradoxically, a monotonic decrease in genital
chlamydial prevalence over time was not observed. Rather,
they observed annual increases in rates of re-infection, with
14 % of all cases reported annually being re-infections
[22, 23]. They postulated that this observation in part arose
as a consequence of early treatment interfering with the de-
velopment of natural immunity to infection. This
phenomenon has been named The Arrested Immunity
Hyposthesis [23], since it hinges upon the successful clear-
ance of infection at the individual level, but the unintended
prevention (or ‘arrest’) of the development of population
immunity.
In this study, we use a published model of trachoma
infection, which includes the development of population
immunity, to explore the impact of treatment and trans-
mission reduction measures on trachoma prevalence. We
also investigate the possibility of adverse outcomes that
may arise as MDA and transmission reduction measures
are scaled up in endemic settings in order to achieve the
GET2020 goal of eliminating blinding trachoma. This
modelling study is complemented by a second study on
trachoma in this issue, which focuses on the utility of




The model analysed here represents ocular (re) infection of
individuals with C. trachomatis as they come into contact
with other infected individuals; it uses a modified compart-
mental susceptible-infected-susceptible (S-I-S) structure,
with the second S state being distinct from the original S,
thereby constituting a ‘ladder of infection’ whose rungs
represent successive infections, i (Fig. 1, and Additional
file 1). The rate of recovery from an episode of infection
increases with each successive infection (hence the
duration of infection decreases following each successive
infection) [17]. The model incorporates this effect by
assuming that with each successive infection the
acquired immune response to infection is enhanced
[25], resulting in increasingly rapid clearance of bac-
teria. Additionally, we assumed that the infectivity of
individuals declines with each successive infection and
this effect is also likely to be a consequence of developed
acquired immunity [14, 15]. Infectivity is assumed to be
proportional to the bacterial infection load an individual
carries. Both of these acquired immunity-modulated
effects are modelled as exponential functions of the num-
ber of successive infections, i, experienced by an individual
[26] (Fig. 1). All parameter values used are provided in the
Additional file 1: Table S1. The original study [26] that
outlined this model simultaneously fitted the parameters
of these immunological functions, and an overall transmis-
sion parameter β, to age-dependent infection prevalence,
duration of infection, and bacterial load data from a set of
hyperendemic communities in Tanzania and Gambia. The
model exhibited disease sequelae incidence rates that
closely matched those published for Kongwa district,
Tanzania, prior to the commencement of an intensive
intervention study [27].
The effect of MDA on the prevalence of infection
We applied two different simulated MDA regimens to
the modelled population; 3 and 10 annual rounds. Each
MDA round had a population coverage level, c, of 85 %
and antibiotic efficacy, e, of 95 % as in the study by
Fig. 1 Schematic diagram of the compartmental model of trachoma
epidemiology analysed here: the ladder of infection model
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Gambhir et al. [28]. Those individuals in the population
for whom an MDA round was successful cleared their in-
fection completely and this was simulated here, as in pre-
vious studies, by shifting the cleared group (a proportion
of the population c × e) from infected compartment i into
susceptible compartment i on the ladder of infection.
Modelling reductions in transmission
The third GET2020 goal states that the F & E compo-
nents of the SAFE strategy should be enhanced in order
to help achieve the elimination of blinding trachoma by
2020. In this study we model enhancement of the F & E
components as an instantaneous drop in the transmis-
sion parameter β when MDA is initiated. However, it
remains challenging for trachoma treatment trials to iden-
tify and demonstrate the efficacy of F & E interventions;
therefore, exactly how much enhanced F & E interven-
tions may reduce transmission remains unknown. A
recent meta-analysis suggested that the potential contribu-
tions of F & E to the reduced odds of trachoma infection
could be very important [29]. As such, we explore two
values of transmission reduction (25 % and 50 %, one feas-
ible and one optimistic; see e.g. [29]). The null assump-
tion, i.e. no F &E impact, is considered here as those
simulations that exclude F & E.
Distribution of the population by the number of
infections experienced
One of the main drivers of a possible change in the
transmission rate relates to the level of population im-
munity. Immunity to infection (but not re-infection) dic-
tates the rate of recovery from an infection episode, and
the bacterial load carried by an individual upon infec-
tion. Here we model these quantities as a function of the
number of prior infections experienced, i (Fig. 1). We
illustrate the changing distribution of the population ac-
cording to the number of prior infections, following each
of the simulated interventions we apply, by plotting a
histogram of the proportion of individuals who have
experienced i infections. We calculated this quantity for
the susceptible population, since the resulting changes in
the distribution are easier to see, though we confirmed
that the overall population (i.e. susceptible + infected)
shift is very similar.
Calculating the effective reproduction number over time
The summary parameter encapsulating the important
aspects of transmissibility in the early stages of an out-
break is the basic reproduction number (R0). However,
R0 would be the appropriate parameter to compute if
the population were entirely susceptible and naïve to in-
fection i.e. if there were no long term acquired immunity
to infection in the population. Here, however, we are in-
terested in the true transmissibility of trachoma infection
in the presence of the current state of the population
and so the relevant summary parameter is the effective
reproduction number (Re), which accounts for popula-
tion immunity. Here, Re is a function of the current dis-
tribution of the population according to the number of
prior infections experienced. We use the Next Gener-
ation Matrix method [30] to calculate Re for our ladder
of infection model structure (see Additional file 1).
Results
The effect of MDA on the prevalence of infection
We present six longitudinal time series following 3
(Fig. 2a-c) and 10 MDA rounds (Fig. 2d-f), the first at base-
line, and the subsequent rounds at annual intervals. For
each transmission setting we considered a prevalence of in-
fection in the community at baseline to be approximately
Fig. 2 Annual MDA treatments in three endemic settings, impact and rebound Each endemic setting is subjected to 3 and 10 annual rounds of
simulated MDA (with coverage and efficacy detailed in the main text, Methods). Infection is essentially eliminated following 3 and 10 rounds in the
hypoendemic setting (a and d), but remains at a detectable level throughout the MDA programme in both meso (b and e)and hyperendemic (c and
f) settings. The rate of rebound of infection increases over time in all settings but, once MDA ceases, its magnitude results in a large overshoot of
infection prevalence beyond its baseline level in the hypo–and mesoendemic settings
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50 %, 15 % and 5 % for hyper, meso and hypoendemic set-
tings respectively (Fig. 2). Note that these baseline preva-
lence levels are slightly different to those used to fit the
model published by Gambhir et al. [26] and were chosen
to more clearly illustrate the results of the present study.
At the therapeutic coverage and drug efficacy levels
chosen, infection prevalence rebounded within the
course of one year following each MDA round in the
hyperendemic setting (Fig. 2c and f ). Stopping treat-
ment after 10 consecutive annual rounds resulted in
no appreciable overall decline in prevalence (Fig. 2f )
as infection re-bounded to pre-intervention levels be-
fore the next round of MDA had begun. However,
infection prevalence was reduced more dramatically in
the mesoendemic setting (Fig. 2b and e), and infection
rebound occurred more slowly between treatments for the
first 3 rounds of MDA. Cessation of treatment 10 years
after commencement also resulted in the re-emergence of
infection (Fig. 2b and e). When 10 MDA rounds were
given, in the hyper- and mesoendemic settings, the rate of
rebound of infection became faster with each subsequent
treatment round (Fig. 2e and f). However, this observed
rate of increase was only apparent in the mesoendemic
community after 3 rounds of MDA had already occurred.
The model suggested that in the hypoendemic case,
infection could be effectively eliminated after 3 annual
treatment rounds. However, a rebound following cessation
of treatment was seen here due to the continuation of
transmission at very low prevalences (<<1 %) in our
(deterministic) model. Note that a deterministic model
does not lend itself to the exploration of the possibility
that infection could fade out due to random chance, nor
can we assess the possibility that infection in the commu-
nity can resurge when transmission is very low; this would
require a stochastic modelling approach.
Distribution of the population by number of infections
experienced
The distribution of individuals along the ladder of infec-
tion was highly dependent upon the transmission par-
ameter, β. As the value of β increased (high levels of β
reflected higher transmission settings) the distribution of
the number of infections experienced by individuals in
the population became wider (Fig. 3). The maximum
number of infections experienced by any individual in the
hyperendemic setting is around 180, 40 in the mesoen-
demic, and 10 in the hypoendemic settings (Fig. 3). Des-
pite a very high level of transmission, there remained a
number of immunologically naive individuals who experi-
enced very few previous infections in the hyperendemic
community (Fig. 3a). These infection-naïve individuals
would be expected to rapidly acquire infection and hence
immunity, but as transmission is reduced, the rate at
which this immunity is acquired is much slower.
The population distributions following 10 simulated
MDA rounds (Fig. 3, dark blue lines) show a marked shift
toward the zero end of the prior infection spectrum. This
shift is greater for the lower endemic settings and results
in an increase in the average recovery rate and infection
load experienced by infected members of the population,
hence the rate at which immunity is acquired is slower.
The biological effect of this population shift is illus-
trated in Table 1, where the average duration of infection
and the infectivity, experienced by an average individual
in the population, are both seen to increase immediately
following MDA treatment. The increase in these average
measures is greater following 10 annual MDA treatment
rounds than it is for 3 rounds.
Effective reproduction number over time
The value of Re rises steadily during the period when
MDA is being applied and eventually falls back down to
its baseline level (Fig. 4). The initial increase and then
gradual decrease of Re over time is larger when MDA is
sustained for 10 rounds in comparison to 3. Additionally,
the increase in Re tends to continue beyond the duration
of MDA as the endemicity decreases, with the extreme
case shown in the upper curve of Fig. 4a (where 10 annual
rounds of MDA are applied). Over 10 years of MDA
within a hypoendemic community, a gradual increase in
Re from a baseline value of 1.0 to a final value of approxi-
mately 1.5 is observed, but this value continues to rise well
Fig. 3 Distribution of the population according to the number of
prior infections experienced. The susceptible population distribution
is plotted for each endemic setting prior to (shaded distribution) and
immediately following (black line) 10 MDA rounds. The effect of the
MDA programme is to shift the population distribution to the left
(i.e. to lower numbers of prior infections experienced), and this effect
is more pronounced as the endemicity declines from hyper–to
hypoendemic. Note the axis difference in a compared to b and c
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after the cessation of MDA. This may mean that Re is
substantially elevated beyond its equilibrium level for sub-
stantially longer than the duration of treatment. Equally,
even if local elimination of infection is achieved within the
hypoendemic community, increases in population level Re
as transmission reduces may make these communities
more susceptible to a large-scale outbreak if infection
were to be re-introduced into the community.
Transmission reduction and MDA together
Exploring the impact of two simultaneous control inter-
ventions within a hyperendemic community—10 rounds
of MDA and a transmission reduction of either 25 % or
50 % at baseline—we observed a steady increase in the
rate of rebound of infection over time (Fig. 5a) following
each round of MDA after transmission reduction was
implemented; this was also reflected in the calculated
value of Re increasing over time (Fig. 5b). When compar-
ing between the two different scenarios, the overall change
in the population distribution per ith infection was greater
with transmission reduction and MDA (Fig. 5c) than seen
when MDA was applied alone (Fig. 3a).
Discussion
In this study we hypothesise that successive MDA treat-
ment rounds and rapid transmission reduction measures
may lead to an increase in transmissibility of trachoma
infection, and an increase in difficulty in controlling disease.
This could be due to the gradual loss of immunity from the
population following treatment. This effect was most pro-
nounced for the lowest prevalence communities, in which
transmission was low and control may be achievable des-
pite it. However, in these communities, while control is
feasible, elimination may become markedly more difficult
over time if Re doubles over 20 years (as in Fig. 4). In hyper-
endemic communities, reductions in immunity result in a
smaller transmissibility rise but, in the context of the
extremely labour-intensive treatment schedules needed to
achieve year-on-year declines in prevalence [14, 31, 32],
even a marginal additional effort will be hard to maintain.
The increasingly rapid return of infection over time can
be explained by the following process: first, sustained treat-
ment prevents the population from progressing towards
greater numbers of infections, which means that the popu-
lation experiences fewer infections, on average; second, due
to the slower rate of acquiring clearing immunity due to
treatment and transmission reduction, individuals remain
infected for longer periods of time, increasing the force of
infection.
While our results in this study are theoretical, the
rationale behind them has a sound biological basis. Re-
cent work by Mitchell et al. [5] found that if protective
immunity to schistosomiasis was short-lived, antibody
levels declined to pre-intervention levels during or after
Fig. 4 The time development of the Re during and following MDA. The effective reproduction number Re is plotted for time points prior to, during and
following a 3 round and 10 round MDA programme for each endemic setting. The downward arrows indicate 3 important time points: 1) commencement
of MDA, 2) cessation of 3 round MDA programme, 3) cessation of 10 round programme. In each setting there is a clear rise in the value of Re over time after
MDA begins, though this rise is more pronounced for lower endemic levels. The rise ends with the conclusion of MDA for the hyperendemic setting, but it
persists beyond the conclusion of MDA as the endemic level declines. a indicates the change in Re within the hypoendemic community. b in green the
change in Re within the mesoendemic community and in red the change in Re within the hyperendemic community
Table 1 Average duration of infection (in months) and infectivity (scaled between a high value of 1 and low of 0) calculated over the
whole population at baseline and following 3 and 10 rounds of MDA, for each of the 3 endemic settings
Hypoendemic Mesoendemic Hyperendemic
Duration Infectivity Duration Infectivity Duration Infectivity
Initially 4.42 0.92 2.95 0.60 2.81 0.19
Post 3 MDAs 4.87 0.93 3.23 0.66 2.82 0.23
Post 10 MDAs 5.86 0.95 3.45 0.71 2.86 0.29
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MDA. However, if immunity was longer-lived and MDA
was assumed to reduce transmission, a large over-shoot
in measured egg count was observed. This modelling
work was supported by antibody data suggesting MDA
and transmission reduction may disrupt the develop-
ment of protective immunity or alter existing popula-
tion immunity [5].
The hypothesis presented in this article has been quanti-
tatively tested just once for trachoma, to our knowledge,
within a mesoendemic community, by Liu et al. [19].
While the authors did not identify a significant change in
Re over the 3 year period analysed, the analysis presented
here suggests that a strong signal of increase in Re may
only become apparent after several years, and that its ini-
tial increase may be small.
Our simulated MDA assumes random allocation of
doses in the population with each treatment, while a per-
sistently untreated group of individuals is also a possibility.
In the latter case, it is likely that the value of Re would in-
crease more slowly and to a lesser overall extent due to a
more rapid reseeding of infection from the untreated group
into the wider population following each treatment round.
The adverse effect we find applies to communities in
which MDA is introduced in isolation, but it may be ex-
acerbated when dramatic transmission reduction mea-
sures are rapidly implemented. Such an outcome has
previously been suggested for malaria [10, 12]. In this in-
stance it is expected that a higher number of severe dis-
ease cases will be observed immediately following the
reduction in transmission, primarily as a result of the
loss of population immunity. Furthermore, epidemio-
logical surveillance data in genital chlamydia infection
has also shown empirical evidence of this effect [22, 23].
It was reported that re-infection rates following the
introduction of an infection control programme resulted
in a 4.6 % per year re-infection rate increase during the
period of study from 1989–2003 [22]. These findings
were complemented with a mathematical transmission
model suggesting that early treatment of infection in-
creased the population’s susceptibility to re-infection
[22]. However, Vickers et al. [33] suggested that the in-
creased rates of re-infection in Canada could mainly be
attributable to an increase in testing volume, implying
that The Arrested Immunity Hypothesis had a less sig-
nificant role on the transmission dynamics than previ-
ously reported [36].
To date, the analysis of serological data collected
through trachoma surveillance has been very limited
[34, 35]. Martin et al. [35] fitted a catalytic model to
serological data in order to identify when changes in
transmission intensity within a Tanzanian community
occurred. The authors used a binary cut-off to deter-
mine whether individuals in the study were seroposi-
tive or seronegative and, during the surveillance
period, they did not identify any individuals who ser-
oreverted, suggesting no loss of population immunity.
However, the use of a binary cut-off to define individ-
uals as seropositive or seronegative can mask changes
in the antibody titres that may occur over time,
meaning that even if an individual’s titre has declined
dramatically, if it does not fall below the cut-off
threshold, they will still be classified as seropositive.
Indeed, Goodhew et al. [34] showed that there was evi-
dence of a significant decline in trachoma antigens for
nearly all age groups 6 months after MDA was applied.
Anti-trachoma antibodies are likely to be associated with
protection although the exact relationship is poorly under-
stood. Antibody titers may decrease over time while an in-
dividual remains seropositive leading to a likely decrease
in protection over time.
Therefore, while the effects presented here remain
to be substantiated with data from treatment and
transmission reduction trachoma trials, we suggest
the effect seen for genital chlamydia and schistosom-
iasis should be motivation to design trials which in-
clude these outcomes.
Fig. 5 Impact and rebound of the prevalence of infection (a), the
effective reproduction number (Re) (b), and the distribution of
individuals according to their number of prior infections for 10 rounds
of MDA (c). (a) The rate of rebound of infection increases over time
but, once MDA ceases, infection initially overshoots then attains its
new endemic equilibrium for both treatment regimens. (b) A similar
time evolution of Re is seen in both transmission reduction regimens:
an abrupt drop with the transmission reduction, a gradual rise during
MDA, followed by a fall and eventual settling to the new steady-state
value. (c) The susceptible population distribution is plotted for the
hyperendemic setting prior to (shaded distribution), immediately
following (blue dashed line) 10 MDA rounds and 25 % transmission
reduction, and immediately following (black solid line) 10 MDA rounds
and 50 % transmission reduction. Note that the feint dotted grey line
represents the ‘MDA only’ case with 10 treatment rounds
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Conclusions
Implications for study design
In this article we have considered the impact of MDA
and transmission reduction interventions across the
whole community; however, the data analysed by Liu
et al. in [19] were collected from 0–5 year olds. It is
possible that, since young children experience the most
‘severe infections’ with respect to having the highest
bacterial loads and slower rates of recovery, shifts in
population level immunity may not manifest themselves
in this age group. However, longer infection durations
may be seen in older age groups which increasingly con-
sist of individuals with less mature immunity as a result
of declines in transmission; this older population was
not observed in the analysis by Liu et al. [19]. Moreover,
studies previously conducted to examine loss of immun-
ity to C. trachomatisremain limited to the analysis of a
small number of communities [22, 36], potentially limit-
ing their power to identify loss of population immunity.
This suggests that in order to monitor whether the
GET2020 goals are being achieved, larger studies that
also monitor the infection and disease status of older
individuals in the population will be important to ensure
that loss of immunity through transmission reduction
does not help to sustain infection within the community.
It may be that a combination of transmission-enhancing
and reducing (so called Allee [37, 38]) effects will deter-
mine the trajectory of the prevalence over time close to
elimination [39]. Lietman et al. demonstrated that a
common linear hazard of infection term in a mechanistic
model is not sufficient to describe trachoma infection
rebound dynamics at low prevalences, and they accounted
for this using a nonlinear adjustment to the hazard [38]. It
is incumbent upon modellers and quantitative parasitolo-
gists to help devise field studies to measure the rate of
return of infection and disease in at least two separate age
groups; these studies could determine whether density
dependent effects are playing a role and what their relative
contribution is.
Implications for the GET2020 goals
The results we present apply directly to the GET2020
goals relating to the reduction of active disease (TF) and
disease sequelae (TT): both MDA and transmission re-
duction (e.g. F & E) interventions may both result in
rises in rates of return of infection and disease over time
due to the loss of population immunity, making the
achievement of the TF and TT goals more challenging.
In addition, we show that this effect may be worse for
lower-endemic communities. However, we note that the
model used in this analysis was deterministic, and there-
fore it is not ideally suited to assess the stochastic fade-
out and elimination of infection within a community.
Therefore the perverse outcome observed in lower
transmission settings may not be a problem if infection
fades out and does not eventually re-emerge in a commu-
nity, as it does in our deterministic model. A reason that
the observed effect is most exacerbated within the
hypoendemic community is that we have assumed im-
munity to infection develops exponentially and, as such,
larger changes in rates of recovery and infectivity will be
seen when people within the community experience a low
number of infections both at baseline and following MDA.
We also show the effect may also be worse for cur-
rently highly-endemic communities in which intensive
SAFE programmes are imposed, as dictated by the third
GET2020 goal, which states that the F & E components
of the SAFE strategy should be enhanced. However, by
reducing the frequency at which individuals become
infected through transmission reduction and MDA, this
will ultimately result in lower equilibrium levels of infec-
tion prevalence and ultimately a lower prevalence of
disease sequelae due to individuals experiencing fewer
infections over their lifetime.
The role of acquired immunity to trachoma remains
poorly understood, but modelling the dynamics associated
with the loss and gain of population immunity is essential
if we are to account for outcomes that, perversely, may re-
sult in transmissibility increases as a result of transmission
reduction measures. Changes in population immunity to
infection as a result of intensive transmission reduction
measures may frustrate the achievement of the GET2020
goals, and field trials need to be designed in order to
monitor and minimise the chance and effects of these
outcomes. This may also mean that longer-term post-
validation surveillance is required to ensure the incidence
of infection does not begin to increase over time, follow-
ing achievement of the GET2020 goals. However, it is
likely the cost of intermittent surveillance will be justified
if we want to achieve the long-term elimination of blind-
ing trachoma.
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